Phenestra's latest white paper highlights the challenges in market access and reimbursement for every company involved in developing new and innovative drugs.
The personalised medicine approach is rapidly becoming the new norm for pharmaceutical industry drug development and commercialisation, but it demands much more forward-thinking decision-making
As the pharma industry becomes more reliant on new products to fill the gap left by the patent cliff, ensuring effective launch for novel treatments is critical.